Literature DB >> 15170818

PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain.

Magnus Schou1, Christer Halldin, Judit Sóvágó, Victor W Pike, Håkan Hall, Balázs Gulyás, P David Mozley, David Dobson, E Shchukin, Robert B Innis, Lars Farde.   

Abstract

(S,S)-2-(alpha-(2-Fluoromethoxyphenoxy)benzyl)morpholine ((S,S)-FMeNER) was found to be a selective high-affinity ligand for the norepinephrine transporter (NET). (S,S)-FMeNER) was labeled with fluorine-18 (t1/2 = 109.8 min) by O-fluoromethylation of desfluoromethoxy-(S,S)-FMeNER with [18F]bromofluoromethane. An analog, di-deuterated in the fluoromethoxy group ((S,S)-FMeNER-D2), was similarly labeled with di-deutero-[18F]bromofluoromethane. These two new radioligands were obtained in radiochemical purities greater than 98% and with specific radioactivities ranging from 111-185 GBq/micromol at the end of synthesis (75 min). After intravenous injection of (S,S)-[18F]FMeNER into cynomolgus monkey, PET examination with the head in the field of view revealed skull-bound radioactivity, contaminating images of the brain, and indicated fast defluorination of the radioligand. Defluorination was much reduced in similar PET experiments with (S,S)-[18F]FMeNER-D2. Ratios of radioactivity in the lower brainstem, mesencephalon, thalamus, and temporal cortex to striatum obtained with (S,S)-[18F]FMeNER-D2 at 160 min after i.v. injection were 1.5, 1.6, 1.3, and 1.5, respectively. In another PET experiment, pretreatment of the monkey with the selective NET inhibitor, desipramine, decreased the radioactivity ratios in all examined regions to near unity (e.g., to a ratio of 1.03 in mesencephalon). Labeled metabolites of (S,S)-[18F]FMeNER-D2 or (S,S)-[18F]FMeNER found in plasma were all more polar than the parent radioligand. In vitro autoradiography of (S,S)-[18F]FMeNER-D2 on post-mortem human brain cryosections furthermore showed specific binding to NET in the locus coeruleus and thalamus. (S,S)-[18F]FMeNER-D2 is the first useful radiofluorinated ligand for imaging brain NET in monkey in vivo and is superior to (S,S)-[11C]MeNER because a specific binding peak equilibrium is obtained during the PET experiment at a lower noise level. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170818     DOI: 10.1002/syn.20031

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  35 in total

1.  Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.

Authors:  Jean-Dominique Gallezot; David Weinzimmer; Nabeel Nabulsi; Shu-Fei Lin; Krista Fowles; Christine Sandiego; Timothy J McCarthy; R Paul Maguire; Richard E Carson; Yu-Shin Ding
Journal:  Neuroimage       Date:  2010-09-30       Impact factor: 6.556

2.  Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands: [C-11]desipramine, [C-11]talopram and [C-11]talsupram.

Authors:  Magnus Schou; Judit Sóvágó; Victor W Pike; Balázs Gulyás; Klaus P Bøgesø; Lars Farde; Christer Halldin
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

3.  Imaging the norepinephrine transporter with positron emission tomography: initial human studies with (S,S)-[18F]FMeNER-D2.

Authors:  Akihiro Takano; Balázs Gulyás; Andrea Varrone; Per Karlsson; Magnus Schou; Anu J Airaksinen; Francois Vandenhende; Johannes Tauscher; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-02       Impact factor: 9.236

4.  Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study.

Authors:  Akihiro Takano; Christer Halldin; Andrea Varrone; Per Karlsson; Nils Sjöholm; James B Stubbs; Magnus Schou; Anu J Airaksinen; Johannes Tauscher; Balázs Gulyás
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-14       Impact factor: 9.236

5.  3-Substituted 1,5-Diaryl-1 H-1,2,4-triazoles as Prospective PET Radioligands for Imaging Brain COX-1 in Monkey. Part 2: Selection and Evaluation of [11C]PS13 for Quantitative Imaging.

Authors:  Stal Shrestha; Prachi Singh; Michelle Y Cortes-Salva; Kimberly J Jenko; Masamichi Ikawa; Min-Jeong Kim; Masato Kobayashi; Cheryl L Morse; Robert L Gladding; Jeih-San Liow; Sami S Zoghbi; Masahiro Fujita; Robert B Innis; Victor W Pike
Journal:  ACS Chem Neurosci       Date:  2018-06-13       Impact factor: 4.418

6.  Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.

Authors:  Sean R Donohue; Joseph H Krushinski; Victor W Pike; Eyassu Chernet; Lee Phebus; Amy K Chesterfield; Christian C Felder; Christer Halldin; John M Schaus
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

7.  SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.

Authors:  Akihiro Takano; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2012-10-23       Impact factor: 4.530

8.  Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands.

Authors:  Garth E Terry; Jussi Hirvonen; Jeih-San Liow; Sami S Zoghbi; Robert Gladding; Johannes T Tauscher; John M Schaus; Lee Phebus; Christian C Felder; Cheryl L Morse; Sean R Donohue; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

9.  [18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography.

Authors:  Julius Leyton; Graham Smith; Yongjun Zhao; Meg Perumal; Quang-De Nguyen; Edward Robins; Erik Arstad; Eric O Aboagye
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

10.  (R)-N-Methyl-3-(3-(125)I-pyridin-2-yloxy)-3-phenylpropan-1-amine: a novel probe for norepinephrine transporters.

Authors:  Balagopal Lakshmi; Mei-Ping Kung; Brian Lieberman; Jun Zhao; Rikki Waterhouse; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.